AAD 2022
Featured articles
Lebrikizumab treatment leads to encouraging outcomes in multiple traits of AD
CONTENTS
Online First
New Developments and Unmet Needs in Dermatology
Light at the end of the tunnel for vitiligo therapy
JAK inhibitors: A risk assessment
Monitoring is key during JAK inhibitor therapy
Intestinal microbe-preparation: Modest activity but safe for mild psoriasis
Alopecia areata: 1-year baricitinib treatment increases success
New anticholinergic preparation is effective and tolerable in hyperhidrosis
What’s Hot in Rare Diseases
Add-on apremilast may improve recalcitrant dermatomyositis
Could dupilumab put an end to the therapeutic draught in prurigo nodularis?
Fungal skin infections in children: A diagnosis to keep in mind
Innovative gel speeds up clearance of molluscum contagiosum lesions
JAK inhibition offers promising treatment prospects for uncommon dermatoses
JAK inhibitors may offer a new horizon in the treatment of sarcoidosis
Psoriasis: State of the Art
New insights into psoriasis comorbidity
Long-term psoriasis treatment with bimekizumab results in maintained efficacy
Novel developments in topical psoriasis therapy
Atopic Dermatitis: Novel Agents Enter the Stage
JAK inhibitors in AD: Setting the efficacy bar even higher
Lebrikizumab treatment leads to encouraging outcomes in multiple traits of AD
Novel IL-4/IL-13 blocker shows high efficacy with only modest conjunctivitis signal
Posters
Inpatient dermatologic therapy is linked to lower mortality and readmission rates
AD treatment during the pandemic: dupilumab does not raise COVID-19 infection risk
